The development of acquired resistance to trastuzumab remains a prevalent challenge in the treatment of patients whose tumors express human epidermal growth factor 2 (HER2). We previously reported that HER2 overexpressing breast cancers are dependent on Y-box binding protein-1 (YB-1) for growth and survival. As YB-1 is also linked to drug resistance in other types of cancer, we address its possible role in trastuzumab insensitivity.
Introduction
Molecular targeted therapies have revolutionized the field of cancer therapeutics (Sawyers, 2004) . Although they prove to be successful in the treatment of cancer patients, there remain many pitfalls with their use. The human epidermal growth factor 2 (HER2), an established proto-oncogene overexpressed in 20-30% of breast cancer patients, defines aggressive disease and is associated with poor prognosis, a shorter disease free period and poor survival (Slamon et al., 1987) . The development of trastuzumab (herceptin), a humanized monoclonal antibody targeting HER2 has provided clinical benefit when administered in combination with conventional chemotherapies (Cobleigh et al., 1999; Slamon et al., 2001) . Unfortunately, the therapeutic efficacy of trastuzumab has been futile in many instances, as many patients do not respond to initial treatment or develop resistance to therapy within 1 year (Slamon et al., 2001; Vogel et al., 2002) . A number of mechanisms have been implicated in the acquisition of resistance; however, they have not provided definitive answers to overcoming the problem.
In this study, we queried the role of Y-box binding protein-1 (YB-1), a transcription/translation factor that is overexpressed in 40% of human breast cancers, in trastuzumab resistance because of its established association with poor survival, disease recurrence and relapse, specifically in the HER2 subtype (Habibi et al., 2008) . Its function in breast cancer growth and survival is eminent by its regulation of epithelial growth factor receptor, HER2, MET, PIK3CA, in addition to its mediation of drug resistance by induction of MDR1 (Bargou et al., 1997; Wu et al., 2006; Stratford et al., 2007; Astanehe et al., 2009; Finkbeiner et al., 2009) . We have previously identified YB-1's role in the growth and survival of HER2 positive breast cancers and demonstrated that it was necessary for in vivo tumorigenesis (Lee et al., 2008) . More recently, our laboratory has confirmed a novel role for YB-1 in the maintenance of a tumor-initiating cell (TIC) phenotype (To et al., 2010) .
Given the recent evidence implicating HER2 as a regulator of TICs and that these cell types are resistant to common chemotherapies, we questioned whether YB-1 has a role in the development of acquired trastuzumab resistance by inducing a TIC phenotype (Korkaya et al., 2008; Li et al., 2008) . As the mode of resistance remains poorly understood, this study provides a novel mechanism by which cancer cells acquire the ability to escape the effects of trastuzumab, and thus a rationale to target YB-1 in the treatment of trastuzumab resistance.
Results and discussion
P-YB-1 S102 is highly expressed in trastuzumab resistant cell lines A recent study by Ritter et al. (2007) demonstrated the in vivo generation of cell lines with acquired trastuzumab resistance, which served as an attractive model to study as it emulates a typical course of clinical therapeutic resistance. Moreover, these resistant cell lines, HR5 and HR6, were shown to express increased levels of the YB-1 target gene EGFR (Ritter et al., 2007) , which we have extensively characterized (Wu et al., 2006; Stratford et al., 2007) . Interestingly, we observed that protein levels of P-YB-1 S102 and its activating kinase P-RSK (Stratford et al., 2008) were significantly higher in the HR5 and HR6 cell lines in comparison to their parental BT474 counterpart (Figure 1a ). Importantly, P-RSK and P-YB-1 S102 levels were persistent in the HR5 and HR6 cell lines following 72 h of trastuzumab treatment, but dropped considerably in the trastuzumab sensitive cell line BT474 (Figure 1b) . RSK phosphorylation has been reported to be an ERK dependent event, however, provided that P-ERK T202/Y204 levels decrease across both trastuzumab sensitive and resistant cell lines, maintenance of RSK activation may instead be an event downstream of PI3K or PDK1 signaling. AKT has previously been linked to trastuzumab resistance and interestingly it has also been demonstrated to phosphorylate YB-1 at serine 102 (Sutherland et al., 2005; Ritter et al., 2007) . Surprisingly, P-AKT S473 levels also diminished with trastuzumab exposure in all three cell lines suggesting that it is not the kinase responsible for maintaining YB-1 phosphorylation.
Trastuzumab resistant cell lines depend on YB-1 for growth and survival We have previously reported on the dependence of HER2 positive breast cancer models on YB-1 for cell survival, growth in vitro and in vivo tumorigenesis (Lee et al., 2008) . Consequently, we inhibited YB-1 with targeting small interfering RNA (siRNA) and found that the loss of YB-1 initiated apoptosis as indicated by increased levels of P-H2A.X S139 and PARP cleavage in all three cell lines (Figure 1c) . Furthermore, we evaluated anchorage independent growth in the BT474, HR5 and HR6 cell lines with YB-1 depletion and found that colony formation was considerably hindered by 60-90%, suggesting that it is essential for the growth and survival of trastuzumab resistant cell lines (Figure 1c ).
YB-1 inhibition further sensitizes cells to trastuzumab and can be used to overcome resistance To determine whether the expression of YB-1 contributes to a cell's response to trastuzumab, we inhibited YB-1 with siRNA with simultaneous drug treatment and measured cell viability in the BT474, HR5 and HR6 cell lines. Interestingly, depletion of YB-1 alone resulted in a 40% reduction in viable cells (Figure 1d ). Further, as displayed in Figure 1d , an B60% reduction in proliferation was observed when cells were treated with trastuzumab amid YB-1 exhaustion. In fact, with the loss of YB-1, both sensitive BT474 and resistant HR5 and HR6 cell lines had similar responses to trastuzumab treatment. In addition, inhibiting YB-1 expression with siRNA suppressed the growth of the BT474-m1 and AU565 cells in soft agar, which are HER2 positive and trastuzumab sensitive, by B60%, moreover, siYB-1 enhanced the sensitivity of these cells to trastuzumab (Supplemental Figure 1) . To elaborate on this, in the BT474-m1 cells, it took 20 mg/ml of trastuzumab to suppress colony formation by 95%. In contrast, only 0.2 mg/ml of trastuzumab was required to have the same effect with simultaneous YB-1 inhibition. Also, pharmacological inhibition of YB-1 activation with BI-D1870, a RSK inhibitor, had a striking effect on growth and resulted in cell death in both sensitive and resistant cell lines (Figures 2a and b ). These findings suggest that a RSK dependent mechanism preserves YB-1 activation to promote resistance to trastuzumab therapy.
BT474 Flag-YB-1 S102D stable clones are trastuzumab resistant BT474 cells expressing Flag-YB-1 S102D , a constitutively active mutant of YB-1, functioning as a phosphomimic, was employed with the intention of generating a cell line capable of phenocopying acquired resistance. We therefore compared the response of all stable cell lines to trastuzumab in a monolayer growth assay. The YB-1 S102D mutant was capable of rendering the cell line insensitive to trastuzumab in contrast to the BT474 EV cell line (Figures 2c and d ). However, P-YB-1 S102A , the inactive mutant did not. Providing further evidence that signal transduction pathways regulated by phosphorylated YB-1 are critical in a cell's ability to escape the effects of trastuzumab.
Trastuzumab resistant cell lines have increased expression of CD44, which is regulated by YB-1 In breast cancers, cells with a CD44 þ CD24 low EpCAM þ phenotype have been defined as TICs (Al-Hajj et al., 2003) . These cells are more tumorigenic as demonstrated by in vivo serial dilution tumor formation assays in addition to their enhanced mammosphere forming abilities when compared with their non-TIC counterparts. More recently, TICs have been implicated in drug resistance and disease recurrence Marangoni et al., 2009) . A study comparing paired tumor biopsies of patients before and after conventional chemotherapy demonstrated that breast cancer cells resistant to treatment were enriched in CD44 þ / CD24 À/low cells, and in fact, these resistant cells had higher mammosphere formation capability compared with the pretreatment samples . We have previously implicated YB-1 as a regulator of a set of common genes associated with a stem cell signature , including CD44. More recently, we demonstrated that YB-1 promotes tumor initiation by inducing CD44, an established TIC marker (To et al., 2010) . Here, we find the HR5 and HR6 cell lines express more CD44 transcripts, as well as protein as compared with the BT474 cells (Figure 3a ), which correlates with increased mammosphere formation (Figure 3b ). There was also more P-YB-1 S102 found in HR5 and HR6 cells grown as mammospheres (Figure 3b) . Further, when grown as mammospheres, the HR5 and HR6 cells expressed more CD44 as demonstrated by immunofluorescence analysis of whole mount mammospheres (Figure 3c ), whereas inhibition of YB-1 impaired mammosphere formation (Figure 3d ). WT or Flag-YB-1 S102D plasmid constructs as described previously ) with 6 ml of Lipofectamine 2000 Reagent (Invitrogen). Cells were continuously maintained in G418 and split at low density. For each construct, four clones were selected, expanded and evaluated for transgene expression, clones expressing the highest level of the transgene were then selected to carry out further experiments. BT474 Flag-EV, Flag-YB-1 WT , Flag-YB-1 S102D and Flag-YB-1 S102A were plated at a density of 3.5 Â 10 4 cells per well into a 12-well plate and treated with 20 mg/ml of trastuzumab for 7 days. Representative photomicrographs demonstrate cells expressing YB-1 S102D were less sensitive to trastuzumab. (d) Following treatment, cell growth was quantified by nuclei staining and immunblot shows transgene expression. Significance was determined using paired Student's t-test and P-values o0.05 were considered significant and represented by a *. Figure 1 Trastuzumab resistant cell lines have increased levels of P-YB-1 S102 and depend on YB-1 for growth and survival. (a) Immunoblot analysis demonstrates trastuzumab resistant cells express increased levels of P-YB-1 S102 protein and its activating kinase P-RSK compared with the sensitive BT474 cell line. Cells were harvested as previously described (Wu et al., 2006) . Primary antibodies used for immunblot were P-YB-1 5 of the indicated cells were seeded in a 6-well dish and treated with trastuzumab (20 mg/ml) for 72 h. Drug treatment decreased P-YB-1 S102 levels in the BT474 cell line, whereas activated YB-1 and RSK levels were sustained in the resistant counterparts. Densitometric analysis was performed to quantify band intensities. (c) BT474, HR5 and HR6 were seeded into a 6-well plate at 3 Â 10 5 cells per well 24 h before transfection. 5 nM of either control (AllStars Negative Control siRNA, #1207820, Qiagen, Hilden, Germany) or YB-1 oligonucleotide #1 or oligonucleotide #2 ) was transfected using Lipofectamine RNAiMAX (Invitrogen) for 96 h. Immunoblot demonstrates the induction of apoptosis as suggested by phosphylation of H2A.X and PARP cleavage. Primary antibodies used were P-gH2A.X S139 , 1:1000 (Abcam) and PARP, 1:1000 (Cell Signaling Technology). After 48 h of siRNA transfection, cells were trypsinized and suspended into 0.3% agar and plated at a density of 5 Â 10 3 cells per well in a 24-well plate on top of a layer of 0.6% agar, colonies were counted after 30 days. YB-1 inhibition markedly attenuated colony formation. (d) BT474, HR5 and HR6 cells were seeded at a density of 5.5 Â 10 4 cells per well in a 24-well plate and allowed to adhere for 24 h. Cells were then treated with 5 nM of either control or YB-1 siRNA. After 24 h, cells were either grown in regular growth media or media supplemented with 20 mg/ml of trastuzumab for 72 h. Following treatment, cell proliferation was evaluated using the CellTiter 96 AQ ueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI, USA). YB-1 knockdown was concurrently confirmed by immunoblot analysis of whole cell extracts. Cell growth was inhibited with siRNA targeting YB-1, the effect was enhanced with the addition of trastuzumab. The results are reported as the mean ± s.d. Significance was determined using paired Student's t-test and P-values o0.05 were considered significant and represented by a *.
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We next employed chromatin immunoprecipitation assays to demonstrate that YB-1 was responsible for the regulation of CD44 by showing promoter binding in our model of resistance, in fact the resistant cell lines displayed increased binding that also correlated to increased CD44 promoter activity (Figure 4a ). The stable expression of YB-1 S102D in BT474 cells had similar effects by increasing CD44 protein levels (Figure 4b) . Similarly to the HR5 and HR6 models, the BT474 YB-1 S102D mutant cell line was more efficient in its ability to form mammospheres and also demonstrated a significant increase in CD44 promoter activity (Figure 4b) . Following, we assessed CD44 levels in the BT474 cell line after trastuzumab treatment for 7 days to ask whether the remaining cells were CD44 positive. Interestingly, of the remaining cells, those that survived treatment had a twofold increase in CD44 transcript levels ( Figure 4c ). Further, when trastuzumab sensitive BT474 cells were grown as mammospheres in the presence of trastuzumab, they were irresponsive to therapy, again suggesting that TIC-like cells are resistant to trastuzumab (Supplemental Figure 2) . This suggests that a subset of (a) Cells were seeded onto glass coverslips at a density of 5 Â 10 5 cells per well and allowed to adhere. Next, cells were fixed with 2% formalin for 20 min and incubated with CD44 conjugated to phycoerythrin, 1:100 (Clone G44-26, Becton Dickinson (BD) Pharmingen, Franklin Lakes, NJ, USA) diluted in immunofluorescence buffer (phosphate-buffered saline (PBS) with 2% goat serum, 1% bovine serum albumin (BSA) and 1% saponin) for 1 h at room temperature. Following, coverslips were incubated in secondary Alexa Fluor 546 goat anti-mouse IgG (Invitrogen) diluted 1:1000 in immunofluorescence buffer for 1 h at room temperature. Lastly, coverslips mounted onto glass slides using Prolong Gold antifade reagent with DAPI (Invitrogen). Cells were imaged on an Olympus Fluorescence BX61 Microscope. RNA isolation, cDNA synthesis and real-time PCR experiments were performed as described previously . TaqMan Universal Master Mix was used with TaqMan Gene Expression Assays designed against CD44 (Hs00153304_m1, Applied Biosystems, Foster City, CA, USA) and TATA-box binding protein (TBP) endogenous control (Part No. 4326322E, Applied Biosystems, Foster City, CA, USA) were used to detect transcript levels on an ABI Prism 7000 Sequence Detector. (b) HR5 and HR6 exhibited increased mammosphere formation. Single cells at a density of 5 Â 10 3 were plated into Ultra-Low Attachment coated 6-well culture plates (Corning, Lowell, MA, USA) in a 1:1 DMEM/F12 basal media freshly supplemented with human basic fibroblast growth factor (Invitrogen), epidermal growth factor (Invitrogen), heparin (Sigma-Aldrich) and B27 supplement without Vitamin A (Sigma-Aldrich). Mammospheres >15 cells in size were counted at 7 days. Protein analysis of mammospheres shows increased levels of P-YB-1 S102 in the resistant cell lines. (c) Cells grown as mammospheres were isolated and stained for CD44. Spheres were resuspended into a 1:1 solution of methanol:acetone and spotted onto glass slides and placed at À20 1C for 10 min and then air dried. Spheres were stained with CD44 conjugated to phycoerythrin, 1:25 (BD) diluted in immunofluorescence buffer (PBS with 2% goat serum, 1% BSA and 1% saponin) overnight at 4 1C and then incubated with secondary antibodies as described above for 1 h at room temperature, followed by nuclei staining with Hoechst33342 (SigmaAldrich) and mounted using Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Spheres were visualized by confocal micrsocopy using the Fluoview FV1000 laser scanning microscope (LSI3-FV1000-inverted). (d) Furthermore, inhibiting YB-1 with siRNA decreased sphere formation efficiency. DAPI, 4 0 ,6-diamidino-2-phenylindole. Significance was determined using paired Student's t-test and P-values o0.05 were considered significant and represented by a *.
P-YB-1 promotes resistance to trastuzumab J Dhillon et al cells exists within the bulk population, which is intrinsically resistant to trastuzumab. Hence, we inhibited CD44 with siRNA with coinciding trastuzumab treatment and demonstrated that the combinatory treatment was capable of significantly reducing the number of viable cells (Figure 4d ). were plated at a density of 1 Â 10 7 in a 15 cm dish for each of control chicken IgY and YB-1 immunoprecipitation antibody pull-down. YB-1 promoter complexes were isolated by chromatin immunoprecipitation using a polyclonal chicken antibody as previously described (Wu et al., 2006) . DNA was purified using the QIAquick PCR purification kit (Qiagen). A primer set designed to flank a YB-1 binding site (ATTG) in the first 2kb of the CD44 promoter was designed with the following sequence, annealing position and optimized annealing temperature (T a ): À1657 to À1900,
PCR amplification demonstrated enhanced binding in the resistant cells. The images were quantified by taking into account nonspecific binding to IgY. CD44 promoter activity was also compared in the BT474 and HR5 cell lines. Cells were plated in 6-well plates (5.5 Â 105 cell per well) and transfected with a 2 kB CD44 promoter construct (Addgene, Cambridge, MA, USA) and a renilla expression vector, pRL-TK (Promega) using FuGene HD Transfection Reagent (Roche, Indianapolis, IN, USA). Cells were harvested 48 h post-transfection in 1 Â PLB buffer (Promega) and luciferase activity was measured. All luciferase measurements were normalized to the renilla readings for the matching sample. (b) BT474 YB-1 S102D cell lines express higher levels of CD44 protein as demonstrated by immunofluorescence and also exhibit an enhanced potential to form mammospheres in addition to a significant increase in CD44 promoter activity. (c) BT474 cells were treated with trastuzumab (20 mg/ml) for 7 days, after which CD44 mRNA levels were assessed by quantitaive reverse transcription PCR. Viable cells following trastuzumab treatment were enriched two-fold in CD44 levels compared with the untreated control. (d) BT474, HR5 and HR6 cells were treated concurrently with 20 nM of CD44 siRNA (Hs_CD44_5_HP Validated siRNA, #SI00299705, Qiagen) and trastuzumab (20 mg/ml), cell viability was assessed following 96 h by MTS assay. ChIP, chromatin immunoprecipitation; DAPI, 4 0 , 6-diamidino-2-phenylindole. Significance was determined using paired Student's t-test and P-values o0.05 were considered significant and represented by a *. P-YB-1 promotes resistance to trastuzumab J Dhillon et al Taken together, we have implicated YB-1 as a mediator of acquired trastuzumab resistance. The ability of YB-1 to induce a TIC phenotype in HER2 positive breast cancer cells desensitizes them to the effects of trastuzumab. Given YB-1's established association with cancer relapse, the ability of this transcription factor to regulate such a tumorigenic sub-population sheds light on its ability to confer drug resistance. In a recent prospective study, high YB-1 expression signified a subset of HER2 positive patients that benefited from more aggressive chemotherapy (Gluz et al., 2009) . Our findings complement current literature correlating cancer recurrence to the inability of therapies to effectively terminate the TIC population within the bulk tumor. To conclude, this study provides insight into a novel mechanism, by which cancer cells acquire trastuzumab resistance. We nominate YB-1 as a candidate for molecularly targeted therapy with the hopes of treating acquired trastuzumab resistance by eliminating the TICs responsible for cancer recurrence and hence relapse.
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